MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib plus osimertinib in EGFRm NSCLC Post-Osimertinib
Journal of Thoracic Oncology(2022)
Abstract
Osimertinib, a 3rd-generation, irreversible, oral EGFR-TKI, is standard of care for patients with EGFRm NSCLC. Early data suggest that savolitinib, an oral, potent, and highly selective MET-TKI, in combination with osimertinib may overcome common acquired MET-based molecular resistance mechanisms following osimertinib monotherapy. The SAVANNAH (NCT03778229) study is investigating the efficacy and safety of targeted combination therapy with savolitinib+osimertinib, and exploring optimum MET detection methods and thresholds to identify patients most likely to respond.
MoreTranslated text
Key words
EGFRm, NSCLC, MET
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined